Alpelisib (BYL719)

目录号：S2814

Molecular Weight(MW): 441.47

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

规格

价格

库存

购买数量

10mM (in 1mL DMSO)	RMB 4864.29	现货
5mg	RMB 3034.22	现货
10mg	RMB 4650.12	现货
20mg	RMB 7115.91	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck该产品发表文献9篇：

Blood, 2015, 10.1182/blood-2014-11-610329

PubMed: 25957390 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4550

PubMed: 30382095 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Oncogene, 2016, 10.1038/onc.2016.216

PubMed: 27345413 ( click the link to review the publication )

Mol Cancer Ther, 2017, molcanther.0415.2016

PubMed: 28119489 ( click the link to review the publication )

Br J Haematol, 2014, 165(1):89-101

PubMed: 24405121 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Anal Biochem, 2018, 547:66-76

PubMed: 29470948 ( click the link to review the publication )

Anticancer Res, 2015, 35(1):175-82

PubMed: 25550549 ( click the link to review the publication )

客户使用该产品的3个实验数据：

AN3CA (B), JHUEM2 (D), and MFE296 (H) cells were treated with the indicated doses of BGJ398 and BYL719 alone or in combination for 96 hours, and an SRB assay was subsequently performed.

Mol Cancer Ther, 2017, 16(4):637-648. Alpelisib (BYL719) purchased from Selleck.

BYL719 induces Apoptosis in MM cells. The effect of increasing concentrations of BYL719 (0-2.5 umol/l) for 48 h on the apoptosis of MM1s cells. The effect of BYL719 on the apoptosis signalling; cleaved PARP, caspase 3, caspase 9 by Western blotting. MM, multple myeloma.

Br J Haematol 2014 165(1), 89-101. Alpelisib (BYL719) purchased from Selleck.
A549 cell was trypsinized and plated at 50% confluence in DMEM. 16 hours later, BYL719 was added at final concentrations of 0, 1, 5, 10 and 20uM. Another 24 hours later, cells were harvested in RIPA with protease and phosphatase inhibitor cocktail. Total protein concentration was measured by BCA method. Lysates equivalent to 20ug total protein were subject to Western Blot, using total- AKT, pS473-AKT, pT286-CyclinD1 and beta-actin (internal control) antibodies.

Alpelisib (BYL719) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

Alpelisib (BYL719) 是一种有效的选择性PI3Kα抑制剂，在无细胞试验中IC50为 5 nM，对PI3Kβ/γ/δ具有极弱的作用。Phase 2。

靶点

PI3Kα ^[1]
(Cell-free assay)

5 nM

体外研究

BYL719抑制含有PIK3CA突变体的乳腺癌细胞系的增殖，与PI3K/Akt通路各种下游信号组分的抑制相关。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
Detroit562	M4jEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\hNFAvOS1zMECg{txO	Mn\DO\|IhcA>?	M1e1cGlEPTB;MT6xNEDPxE1?	M333eVI2PTVyNUS5
SNU-1076	M3;aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37XeVAvOS1zMECg{txO	NEj3Wlc4OiCq	NVW0OJNYUUN3ME22MlgzKM7:TR?=	NXu1e41vOjV3NUC1OFk>
SNU-1066	NIr5[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHny[XUxNjFvMUCwJO69VQ>?	MluxO\|IhcA>?	NH;r[nhKSzVyPUGuNVMh\|ryP	MXyyOVU2ODV2OR?=
FaDu	NUj4W\|RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX2wMlEuOTByIN88US=>	MX[3NkBp	M1PC[mlEPTB;MUmuOlYh\|ryP	Ml2wNlU2PTB3NEm=
SNU1041	NXzMWoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[wMlEuOTByIN88US=>	M2PnWFczKGh?	MnntTWM2OD1{MD62OUDPxE1?	Ml7GNlU2PTB3NEm=
SCC25	M1TKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDkVoQxNjFvMUCwJO69VQ>?	MonqO\|IhcA>?	M3ruO2lEPTB;NEmuN\|Ah\|ryP	NHXVem8zPTV3MEW0PS=>
BON-1	NWPPcVFPTnWwY4Tpc44hSXO\|YYm=	NEHRNWEyNzFyIN88US=>	NV\qRYNiPCCq	M2O0SolvcGmkaYTzJHBKO0tiKFHLWEBU\XJ\|MEipJIFv\CCvVF;SR\|EwOiCjY4Tpeol1cWW\|	NFziVYYzPTB{NkK5Ni=>
QGP-1	Mk\XSpVv[3Srb36gRZN{[Xl?	NW\TUmtnOS9zMDFOwG0>	NXrMZ2VDPCCq	NFHJ[2NqdmirYnn0d{BRUTONIDjBT3QhW2W{M{C4LUBidmRibWTPVmMyNzJiYXP0bZZqfGmncx?=	M3jXRVI2ODJ4Mkmy
MG-63	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MofqTWM2OD14IN88Ug+9lCCLQ{mwQVI1KM7:TR?=	NV\xbYFZOjR7NkG3PVA>
HOS	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEPjbXBKSzVyPUG1JO69Ve,:jDDJR\|kxRTR{IN88US=>	MUSyOFk3OTd7MB?=
MOS-J	NVLU[Y5FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NH20UnVKSzVyPUGwJO69Ve,:jDDJR\|kxRTN4IN88US=>	MXmyOFk3OTd7MB?=
POS-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4TMbWlEPTB;ODFOwG3wxIxiSVO5NF0{PiEQvF2=	Mkj2NlQ6PjF5OUC=
92.1	M2fEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4POSlUxOC1{MECwJI5O	NXK1W2lmPSCm	M3TN[YlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO	NYO5NlJ[OjR3NkO1OFA>
Mel270	MlTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7MOVAxNTJyMECgcm0>	NH3y[XU2KGR?	NXXa[FBxcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1?	M{LmSlI1PTZ\|NUSw
Omm1.3	NHPn[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[3TlU2ODBvMkCwNEBvVQ>?	NYm0SZRQPSCm	MlOzbY5pcWKrdIOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDS2SgLHNmejR5MzmgeZAhfG9iMTFOwG0>	MmDXNlQ2PjN3NEC=
Omm1	NEjITlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;HRog2ODBvMkCwNEBvVQ>?	NFX1TVU2KGR?	M3rmXIlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO	NXj4WWkxOjR3NkO1OFA>
C918	M4PyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEL2blc2ODBvMkCwNEBvVQ>?	MUO1JIQ>	NXjwNIJtcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDBT3QhMFOnckS3N{khfXBidH:gNUDPxE1?	M3vHdFI1PTZ\|NUSw
Mel290	NHPaS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi1bItlPTByLUKwNFAhdk1?	NF;HNlg2KGR?	M1rrPYlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvUJEhU\XJ2N{OpJJVxKHSxIEGg{txO	NGfKc28zPDV4M{W0NC=>
OPM2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHne3UxNjVvMj61JO69VQ>?	NUjwOJJvPDhiaB?=	NXLrbohEcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MYmyOFQxPTF{MR?=
OPM1	M1focGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3NZZYxNjVvMj61JO69VQ>?	NUn5[GJPPDhiaB?=	M{\5TYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	MnjZNlQ1ODVzMkG=
U266	M3n1VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe4bJYxNjVvMj61JO69VQ>?	NIW0Znk1QCCq	M3\tOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M2jVdVI1PDB3MUKx
MM1R	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYKwMlUuOi53IN88US=>	NEjoeWg1QCCq	MU\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M4i3dVI1PDB3MUKx
MM1S	M2i1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXSNE42NTJwNTFOwG0>	M3rBXlQ5KGh?	MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MlLwNlQ1ODVzMkG=
H929	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TsTVAvPS1{LkWg{txO	M2TCRlQ5KGh?	MWXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NX75XnJmOjR2MEWxNlE>
RPMI	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPnfWwxNjVvMj61JO69VQ>?	NFjx[W81QCCq	M1vQNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M1jSZVI1PDB3MUKx
SKBR3	NVXMUYMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTqWJVNOzNizszN	M3m3OFUh\A>?	M1zMZ4lvcGmkaYTzJFM297zHIHPlcIwh\3Kxd4To	MWCyN\|kyQDd7Nx?=
MDA453	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4iyXFM{KM7:TR?=	NHPBOIk2KGR?	MVvpcohq[mm2czCzPQ+9jSClZXzsJIdzd3e2aB?=	NI\mRnAzOzlzOEe5Oy=>
EFM192A	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;XXZFIOzNizszN	NXnHb2FjPSCm	MmjybY5pcWKrdIOgNlfwxIViY3XscEBoem:5dHi=	M2fCd\|I{QTF6N{m3
AU565	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUWzN{DPxE1?	M2rje\|Uh\A>?	MU\pcohq[mm2czCyOw+9jSClZXzsJIdzd3e2aB?=	MknzNlM6OTh5OUe=
MDA361	M17nUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvqWpM{OzNizszN	MUC1JIQ>	MonibY5pcWKrdIOgOFTwxIViY3XscEBoem:5dHi=	M{S0SVI{QTF6N{m3
BT474	NELiWpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnm[\|NKOzNizszN	M2H6[lUh\A>?	NGDJNmpqdmirYnn0d{AyPu,:hTDj[YxtKGe{b4f0bC=>	NYX3dnJQOjN7MUi3PVc>
HCC202	NIGycGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rW[\|M{KM7:TR?=	MmS0OUBl	M4LidYlvcGmkaYTzJFIx97zHIHPlcIwh\3Kxd4To	NVjCOndSOjN7MUi3PVc>
KPL4	NW\QfXl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDnN\|Mh\|ryP	MWi1JIQ>	MUPpcohq[mm2czC1PQ+9jSClZXzsJIdzd3e2aB?=	NXrZeHhZOjN7MUi3PVc>
NCL-N87	NVrZVWdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU[3VmZjOzNizszN	M4fRW\|Uh\A>?	NV\DRWhwcW6qaXLpeJMhOzIxvJWgZ4VtdCCpcn;3eIg>	MY[yN\|kyQDd7Nx?=
UACC812	NW\DU3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvuN\|Mh\|ryP	Mn3vOUBl	NGDlUoNqdmirYnn0d{AzP+,:hTDj[YxtKGe{b4f0bC=>	M3T5c\|I{QTF6N{m3
HCC2218	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUSzN{DPxE1?	MlXHOUBl	M3fv[YlvcGmkaYTzJFE297zHIHPlcIwh\3Kxd4To	Mm\1NlM6OTh5OUe=
HCC1569	NFPZV4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorLN\|Mh\|ryP	NF;CW5Q2KGR?	NV;j[W5xcW6qaXLpeJMhPe,:hTDj[YxtKGe{b4f0bC=>	MWeyN\|kyQDd7Nx?=
OE19	NXjuNmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjFNYM{OyEQvF2=	NHnveJU2KGR?	NHnNXIJqdmirYnn0d{AzO+,:hTDj[YxtKGe{b4f0bC=>	NUDqTVJMOjN7MUi3PVc>
OE33	NYLlNlY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDZN\|Mh\|ryP	NUT6fXNsPSCm	MYHpcohq[mm2czCyN-+9jSClZXzsJIdzd3e2aB?=	M4XwbVI{QTF6N{m3
JIMT1	NHK5dmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j0fVM{KM7:TR?=	NHzGZXc2KGR?	MV;pcohq[mm2czC589yGKGOnbHyg[5Jwf3Sq	MXiyN\|kyQDd7Nx?=
HCC1954	NVrkV29{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVL0eFZUOzNizszN	NYP6eYQ6PSCm	M{ntRYlvcGmkaYTzJFI697zHIHPlcIwh\3Kxd4To	MkPKNlM6OTh5OUe=
NUGC4	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Pp[lM{KM7:TR?=	NIracGs2KGR?	MYHpcohq[mm2czCxOQ+9jSClZXzsJIdzd3e2aB?=	NV6xemJMOjN7MUi3PVc>
ZR-75-30	M2j3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3SWJQ{OyEQvF2=	M2n1UFUh\A>?	MX7pcohq[mm2czCtNVXwxIViY3XscEBoem:5dHi=	NGXx[GkzOzlzOEe5Oy=>

... Click to View More Cell Line Experimental Data

体内研究

BYL719(>270 mg/d)在PIK3CA突变体异种移植啮齿动物模型中表现出统计学显著的剂量依赖性抗肿瘤效能。BYL719具有低清除率，半衰期为8.5小时，并且它的作用在30mg/d 和450mg/d之间剂量成比例的增加，在人的Cmax 和AUC中显示出低的个体差异。BYL719(270mg/d)首次表现出临床疗效的迹象，包括在ER+乳腺癌患者中证实的部分响应，以及17个患者中8个实现了显著的PET响应(PMR)和/或肿瘤治愈。^[1]

参考文献

[1] Dejan Juric, et al. 2012, AACR 103rd Annual Meeting. Abst CT-01.

溶解度 (25°C)

体外	DMSO	88 mg/mL (199.33 mM)
	Ethanol	2 mg/mL (4.53 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG400+0.5% Tween80+5% propylene glycol	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Alpelisib (BYL719) SDF

分子量	441.47
化学式	C₁₉H₂₂F₃N₅O₂S
CAS号	1217486-61-7
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	N/A

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03207529	Not yet recruiting	Malignant Neoplasm of Breast	M.D. Anderson Cancer Center\|Novartis\|Astellas Pharma Global Development Inc.	March 31 2019	Phase 1
NCT03207529	Not yet recruiting	Malignant Neoplasm of Breast	M.D. Anderson Cancer Center\|Novartis\|Astellas Pharma Global Development Inc.	March 31 2019	Phase 1
NCT03631953	Not yet recruiting	Meningioma	Assistance Publique Hopitaux De Marseille	January 1 2019	Phase 1
NCT03631953	Not yet recruiting	Meningioma	Assistance Publique Hopitaux De Marseille	January 1 2019	Phase 1
NCT03601507	Recruiting	CDKN2A-p16 Positive\|Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma\|Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7\|Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7\|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7\|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7	University of Arizona\|National Cancer Institute (NCI)	December 14 2018	Phase 2
NCT03601507	Recruiting	CDKN2A-p16 Positive\|Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma\|Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7\|Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7\|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7\|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7	University of Arizona\|National Cancer Institute (NCI)	December 14 2018	Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

泛PI3K抑制剂

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
活性最高的PI3K抑制剂

BEZ235 (NVP-BEZ235, Dactolisib) : p110α/γ/δ/β, IC50=4 nM/5 nM/7 nM/75 nM.
FDA批准的PI3K抑制剂

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
最新的PI3K抑制剂

VS-5584 (SB2343) ^New : Potent and selective dual PI3K/mTOR inhibitor for mTOR, PI3Kα/β/δ/γ with IC50 of 3.4 nM and 2.6-21 nM, respectively.

研究领域

产品类型

Alpelisib (BYL719)

客户使用Selleck该产品发表文献9篇：

客户使用该产品的3个实验数据：

产品安全说明书

PI3K抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Alpelisib (BYL719) SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2019-03-27)

技术支持

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品